

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.



May 9, 2023

To whom it may concern

Company name: JMDC Inc.
Representative: Yosuke Matsushima,
President and CEO
(TSE Prime Market, Stock Code: 4483)
Contact: Yuta Yamamoto,
Vice President and CFO
(E-mail: ir@jmdc.co.jp)

Announcement of Replacement of President

JMDC Inc. (the “Company”) announces that at the meeting of its Board of Directors held on May 9, 2023, the Company informally decided to replace its President. This matter will be officially decided after its Annual General Meeting of Shareholders to be held in June of this year and the subsequent meeting of its Board of Directors.

1. Reason for Replacing the President

Under its corporate philosophy of “A healthy and prosperous life for all people,” the Company aims to realize a sustainable healthcare system by using the power of data and ICT to solve issues in the healthcare field, such as rising medical expenses and regional disparities in medical care, which are discussed. Specifically, the Company provides a variety of support to further optimize medical care for all patients by accumulating the data generated by players in the healthcare industry and broadly sharing it with society. In order to achieve this goal, the Company has been actively conducting business development, including mergers and acquisitions. Last year, the Company made the following companies its subsidiaries: ClinCloud Ltd. (a provider of Electronic Data Capture (EDC) services); Imepro Inc. (which has full support functions as a Contract Research Organization (CRO)); and Real World Data Co., Ltd. (which has access to the largest electronic medical record database in Japan, mainly from large scale medical institutions). Through these mergers and acquisitions, the Company started new initiatives with a view towards clinical trials and other areas.

In addition, in February last year, the Company entered into a capital and business alliance with Omron Corporation. In March of this year, the Company announced the establishment of the Health Management Alliance to jointly create solutions for the formulation of health management and the generation of results, and to realize implementation of these solutions in industry. Through these, the

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

Company is promoting initiatives to expand our business domain.

Under these circumstances, the Company has determined that it is appropriate to establish a new management system to promote its business even more quickly in response to rapid changes in the business environment surrounding the Company and its group and to make management decisions in a flexible, smooth, and appropriate manner.

2. Details of Replacement

Name	New position	Current position
Yosuke Matsushima	Chairman and Representative Director	President and CEO
Ryo Noguchi	President and CEO, Representative Director	Executive Officer

3. Brief Personal History of Newly Appointed President

Please refer to attached sheet 1.

4. Scheduled Date of Replacement

Late June 2023 (date of the Annual General Meeting of Shareholders)

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

Attached sheet 1: Details of Replacement

Name	Ryo Noguchi	
Date of birth	August 27, 1980	
Educational background	2007 Graduated from Osaka University School of Medicine	
Employment history	April 2007	Joins the Boston Consulting Group, Inc.
	September 2016	Joins NK Relations LLC (currently Noritsu Koki Co., Ltd.)
	October 2016	Appointed as Representative Director, GeneTech K.K.
	June 2017	Appointed as Representative Director, Japan Regenerative Medicine Co., Ltd. (currently Metcela Inc.)
	June 2018	Appointed as Director, Gene Technoscience Corporation (currently Kidswell Bio Corporation)
	July 2020	Appointed as Executive Officer of the Company (in charge of Pharmaceutical Business Division)
	April 2022	Appointed as Executive Officer of the Company (in charge of Payer Support Business Division)
	December 2022	Appointed as Executive Officer of the Company (in charge of Medical Institution Support Business Division)
Number of shares held	24,896 shares (as of March 31, 2023)	

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

Attached sheet 2: Board of Directors structure after the Annual General Meeting of Shareholders in late June 2023 (planned)

Position	Name
Chairman and Representative Director	Yosuke Matsushima
President and CEO, Representative Director	Ryo Noguchi
Director	Yuta Yamamoto
Outside Director	Jihyun Lee
Outside Director	Seiji Takeda
Outside Director who is a member of Audit and Supervisory Board	Tsuneo Shimoda
Outside Director who is a member of Audit and Supervisory Board	Nanpei Hayashi
Outside Director who is a member of Audit and Supervisory Board	Daisuke Fujioka